Provided by Tiger Fintech (Singapore) Pte. Ltd.

Reviva Pharmaceuticals Holdings, Inc.

0.8669
-0.0057-0.65%
Post-market: 0.90000.0331+3.82%19:58 EDT
Volume:346.22K
Turnover:301.89K
Market Cap:40.52M
PE:-0.96
High:0.9170
Open:0.8818
Low:0.8511
Close:0.8726
Loading ...
Mar 22, 2021

Major Issues Report

8-K - Current report
Mar 22, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Mar 04, 2021

Major Issues Report

8-K - Current report
Jan 20, 2021

Major Issues Report

8-K/A [Amend] - Current report
Jan 19, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jan 19, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jan 19, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jan 14, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jan 08, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 07, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Jan 07, 2021

Correspondence

CORRESP [Cover] - Correspondence
Dec 29, 2020

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Dec 21, 2020

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Dec 18, 2020

Major Issues Report

8-K - Current report
Dec 14, 2020

Major Issues Report

8-K - Current report
Dec 14, 2020

Delisting

25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Dec 09, 2020

Major Issues Report

8-K - Current report
Nov 19, 2020

Business Combinations

425 - Prospectuses and communications, business combinations
Nov 19, 2020

Major Issues Report

8-K - Current report
Nov 13, 2020

Major Issues Report

8-K - Current report